| abstract |
(57) [Summary]nThe present invention relates to the use of a selective alpha-2B-adrenergic receptor antagonist for the manufacture of a pharmaceutical preparation useful for treating or preventing a disease mediated by alpha-2B-adrenergic receptor in a mammal. The antagonist is a compound selected from the group consisting of compounds A, B, C, D and E disclosed in Scheme I, or a pharmaceutically acceptable salt of said compound. The present invention also relates to a method for preventing or treating a disease mediated by an alpha-2B-adrenergic receptor in a mammal. The method comprises administering to the mammal an effective amount of the selective alpha-2B-adrenergic receptor antagonist. |